Burning Rock focuses on providing comprehensive cancer genomic solutions for pharmaceutical companies from biomarker discovery to commercialization. Powered by our multimodal central lab testing, integrated companion diagnostic development and commercialization, Burning Rock facilitates the entire process of anti-cancer drug development.

Burning Rock offers integrated central lab services for biopharma partners, from multimodal sample testing to data analysis, meeting drug developing requirements, with five industry-leading qualifications (CLIA, CAP, NCCL, NMPA, ISO15189) and a full spectrum of diagnostic products. So far, we have provided central lab services for >70 pharmaceutical companies in >200 clinical research studies, covering clinical study sites globally.

CDx Development & Commercialization

Burning Rock offers integrated companion diagnostic （CDx） development services for biopharma partners to streamline the codevelopment and commercialization of targeted drug and respective CDx. Our US-based lab and R&D team provide additional services to promote drug and CDx co-development worldwide.

Precision Patient Recruitment

Burning Rock assists clinicians in understanding the inclusion criteria of pharmaceutical company, helps on clinical trial initiation via targeting cancer patients with specific biomarkers, with our own proprietary large-scale genomic database and multiple online resources.